

1                   **Multomics identifies unique modulators of calf muscle**  
2                   **pathophysiology in peripheral artery disease and chronic kidney**  
3                   **disease**

4  
5   Kyoungrae Kim<sup>1</sup>, Trace Thome<sup>1</sup>, Caroline Pass<sup>1</sup>, Lauren Stone<sup>1</sup>, Nicholas Vugman<sup>1</sup>, Victoria Palzkill<sup>1</sup>,  
6   Qingping Yang<sup>1</sup>, Kerri A. O'Malley<sup>2</sup>, Erik M. Anderson<sup>2</sup>, Brian Fazzino<sup>2</sup>, Feng Yue<sup>3,5</sup>, Scott A. Berceci<sup>2</sup>,  
7   Salvatore T. Scali<sup>2</sup>, Terence E. Ryan<sup>1,4,5,#</sup>

8  
9   <sup>1</sup>Department of Applied Physiology and Kinesiology

10   <sup>2</sup>Department of Surgery

11   <sup>3</sup>Department of Animal Sciences

12   <sup>4</sup>Center for Exercise Science

13   <sup>5</sup>Myology Institute

14   The University of Florida, Gainesville, FL, USA

15  
16   **Running Head:** Multomics in PAD and CKD

17  
18   **#Correspondence:** Terence E. Ryan, PhD: 1864 Stadium Rd, Gainesville, FL, 32611. Tel: 352-294-1700  
19   (office); email: [ryant@ufl.edu](mailto:ryant@ufl.edu); Twitter: @TerenceRyan\_PhD

20  
21   **KEYWORDS:** peripheral artery disease, renal, uremia, mitochondria, muscle

22  
23   Manuscript word count: 3900

24 Abstract word count: 346

25 Running head character count: 25

26 Number of references: 68

27 Number of Grayscale figures: 0

28 Number of color figures: 7

29 Number of tables: 1

30

31 Table and Figure count: 8

32

### 33 **ABSTRACT**

34

35 **BACKGROUND:** Chronic kidney disease (CKD) has emerged as a significant risk factor that accelerates  
36 atherosclerosis, decreases muscle function, and increases the risk of amputation or death in patients  
37 with peripheral artery disease (PAD). However, the modulators underlying this exacerbated  
38 pathobiology are ill-defined. Recent work has demonstrated that uremic toxins are associated with limb  
39 amputation in PAD and have pathological effects in both the limb muscle and vasculature. Herein, we  
40 utilize multiomics to identify novel modulators of disease pathobiology in patients with PAD and CKD.

41 **METHODS:** A cross-sectional study enrolled four groups of participants: controls without PAD or CKD  
42 (n=28), patients with PAD only (n=46), patients with CKD only (n=31), and patients with both PAD and  
43 CKD (n=18). Both targeted (uremic toxins) and non-targeted metabolomics in plasma were performed  
44 using mass spectrometry. Calf muscle biopsies were used to measure histopathology, perform bulk and  
45 single-nucleus RNA sequencing (snRNAseq), and assess mitochondrial function. Differential gene and  
46 metabolite analyses, as well as pathway and gene set enrichment analyses were performed.

47 **RESULTS:** Patients with both PAD and CKD exhibited significantly lower calf muscle strength and smaller  
48 muscle fiber areas compared to controls and those with only PAD. Compared to controls, mitochondrial  
49 function was impaired in CKD patients, with or without PAD, but not in PAD patients without CKD.

50 Plasma metabolomics revealed substantial alterations in the metabolome of patients with CKD, with  
51 significant correlations observed between uremic toxins (e.g., kynurenine, indoxyl sulfate) and both  
52 muscle strength and mitochondrial function. RNA sequencing analyses identified downregulation of  
53 mitochondrial genes and pathways associated with protein translation in patients with both PAD and  
54 CKD. Single nucleus RNA sequencing further highlighted a mitochondrial deficiency in muscle fibers  
55 along with unique remodeling of fibro-adipogenic progenitor cells in patients with both PAD and CKD,  
56 with an increase in adipogenic cell populations.

57 **CONCLUSIONS:** CKD significantly exacerbates ischemic muscle pathology in PAD, as evidenced by  
58 diminished muscle strength, reduced mitochondrial function, and altered transcriptome profiles. The  
59 correlation between uremic toxins and muscle dysfunction suggests that targeting these metabolites  
60 may offer therapeutic potential for improving muscle health in PAD patients with CKD.

61

## 62 **ABBREVIATIONS**

63 CKD = chronic kidney disease; GFR = glomerular filtration rate; GSEA = gene set enrichment analysis;  
64 OXPHOS = oxidative phosphorylation; PAD = peripheral arterial disease; ROS = reactive oxygen species;  
65 snRNAseq = single nucleus RNA sequencing

66

## 67 **INTRODUCTION**

68 Peripheral arterial disease (PAD) is a condition characterized by atherosclerosis in the blood vessels of  
69 the lower extremities, affecting approximately 8-12 million Americans, and is a leading cause of  
70 cardiovascular mortality<sup>1,2</sup>. Common risk factors for PAD include age, smoking, diabetes, hypertension,  
71 and dyslipidemia. Notably, chronic kidney disease (CKD) is also strongly associated with PAD,  
72 contributing to the development of atherosclerosis, decreased muscle function, and an increased risk of  
73 amputation or death in patients with PAD<sup>3-9</sup>. Furthermore, CKD is linked to higher failure rates of both  
74 endovascular and open surgical revascularization procedures, which are commonly used in the  
75 management of PAD<sup>3,10</sup>. Recent work has reported a strong correlation between uremic metabolites—  
76 accumulating in CKD—and the risk of adverse limb events in patients with PAD<sup>11</sup>. Both PAD and CKD  
77 have been associated with skeletal muscle myopathy<sup>12-24</sup>, suggesting that muscle tissue may be a key  
78 site where these two diseases intersect. Importantly, muscle function and exercise performance have

79 been established as strong predictors of morbidity and mortality in patients with PAD<sup>13,15,25-27</sup>. Despite  
80 these associations, the mechanisms underlying the exacerbated skeletal myopathy in patients with both  
81 PAD and CKD remain poorly understood. A deeper analysis could reveal novel targets for preventing or  
82 ameliorating muscle pathology in these patients. This cross-sectional study aimed to characterize the  
83 impact of PAD and CKD on skeletal muscle pathology by comparing calf muscle strength, mitochondrial  
84 function, and histopathology in four groups: 1) PAD patients, 2) PAD with CKD patients, 3) CKD patients,  
85 and 4) non-PAD and non-CKD controls. A multiomic approach, including bulk and single nucleus RNA  
86 sequencing of calf muscle specimens and both targeted and untargeted plasma metabolomics, was  
87 employed to identify novel regulators of skeletal muscle pathology

88

89 **MATERIALS AND METHODS.** Detailed descriptions of the materials and experimental procedures can be  
90 found in the Expanded Material and Methods section of the **Supplemental Material**. The data  
91 supporting the conclusions of this study are available from the corresponding author. A Major Resources  
92 Table is available in the **Supplemental Material**.

93

94 Study Population. This was a cross-sectional study involving participants without PAD or CKD, those with  
95 PAD only, those with CKD only, and those with both PAD and CKD. Participants were recruited through  
96 UF Health and the Malcom Randall VA Medical Centers in Gainesville, FL. This study was approved by  
97 the institutional review boards at the University of Florida and the Malcom Randall VA Medical Center  
98 (Protocol IRB201801553). All study procedures were carried out according to the Declaration of Helsinki  
99 and participants were fully informed about the research and informed consent was obtained. Patients  
100 with a normal ABI (greater than 0.9) or those with an abnormal ABI (less than 0.9) indicating a diagnosis  
101 of PAD with a Rutherford Stage between 3-5 set as inclusion criteria. Patients with non-atherosclerotic  
102 occlusive disease were excluded (acute limb ischemia, vasculitis, Buerger's disease, etc.). Inclusion  
103 criteria for CKD included an estimated glomerular filtration rate (eGFR) between 15 and 50  
104 mL/min/1.73m<sup>2</sup> for greater than three months. Medical history, race, smoking history, and  
105 demographics were obtained by self-report. Co-existing medical conditions and medication usage was  
106 obtained through review of medical records. Non-PAD controls were recruited within the University of  
107 Florida Hospital System and Malcom Randall VA medical center and were free from peripheral vascular  
108 disease.

109

110 Calf muscle testing. A detailed description of analysis of calf muscle strength, muscle biopsy technique,  
111 mitochondrial function, muscle histopathology, and bulk and single nucleus RNA sequencing can be  
112 found on the **Supplemental Material**.

113

114 Plasma Metabolomics. A blood sample was obtained from a peripheral antebachial vein using EDTA  
115 tubes and was subsequently centrifuged and plasma was frozen at  $-80^{\circ}\text{C}$  until analysis. Sample  
116 underwent untargeted metabolomic analysis (Global Discovery platform) at a core laboratory using a  
117 well-validated Ultrahigh Performance Liquid Chromatography-Tandem Mass Spectroscopy (UPLC-  
118 MS/MS) platform (Metabolon, Inc.; Morrisville, NC, USA). The platform combines multiple sample  
119 preprocessing protocols and a comprehensive reference library, resulting in quantitative estimates of  
120 metabolite abundance covering a broad spectrum of chemical classes, including amino acids,  
121 carbohydrates, lipids, nucleotides, peptides and vitamins, xenobiotic substances, and pharmaceutical  
122 and food preservative compounds. A detailed description of the analytical protocol, metabolite  
123 identification, and normalization procedures is included in the Supplementary Methods. Samples were  
124 randomized across the platform run with quality control samples spaced evenly among the injections.  
125 Metabolite abundance was estimated from the area under the curve for annotated peaks in the mass  
126 spectrogram (mass spectral counts) and was normalized for batch and run day. Samples were also  
127 processed for targeted metabolomic analysis of kynurenine, tryptophan, 3-indoxyl sulfate, p-cresol  
128 sulfate (pCS), 4-ethylphenyl sulfate (4-EPS), 3-indolelactic acid, and 3-indolepropionic acid in which  
129 quantitative analysis was performed using standard curves for each metabolite.

130

131 Statistical analysis. Normality of data was tested with the Shapiro-Wilk test and inspection of QQ plots.  
132 Data involving comparisons of normally distributed data from groups were analyzed using a one-way  
133 ANOVA. Data involving comparisons of non-normally distributed data from groups were analyzed using  
134 a Kruskal-Wallis test. When appropriate, Tukey's posthoc testing was used to assess differences  
135 between groups. To assess relationships between two variables, Pearson correlation analysis was  
136 employed. Chi-Square analysis was used to determine differences in population proportions for relevant  
137 clinical characteristics. For bulk and snRNAseq, the Benjamini-Hochberg method was used to calculate  
138 false discovery rate corrected  $P$ -values. In all cases,  $P < 0.05$  was considered statistically significant. All

139 statistical testing was conducted using R-studio, Python, or GraphPad Prism software (version 9.0). Data  
140 are presented as the mean  $\pm$  standard deviation unless otherwise specified.

141

## 142 **RESULTS**

143 **Patients with PAD and CKD have significantly lower calf muscle strength and myofiber areas.** Forty-  
144 six patients with PAD with normal kidney function, 18 patients with PAD and CKD, 31 patients with CKD  
145 only (no PAD), and 28 people with PAD or CKD were included in this study (N=123 total). The participant  
146 characteristics are shown in **Table 1**. Calf muscle (plantar flexors) strength was significantly lower in  
147 patients with PAD ( $P=0.0409$ ), patients with CKD ( $P=0.0193$ ), and patients with PAD and CKD ( $P<0.0001$ )  
148 when compared with controls that were free from PAD and CKD (**Figure 1A**). PAD patients with CKD had  
149 significantly lower calf muscle strength than PAD patients with normal kidney function ( $P=0.0103$ ). After  
150 normalizing calf muscle strength to body weight, significant differences remained for PAD vs. PAD+CKD  
151 and control vs. PAD+CKD comparisons. Analysis of the mean myofiber cross sectional area demonstrated  
152 that PAD, CKD, and PAD+CKD groups had significantly smaller Type I and Type II myofibers compared to  
153 control participants (**Figure 1B,C**), however, the relative proportion fiber types was not significantly  
154 different (**Figure 1D**). Within the cohort, a significant correlation (Pearson  $r = 0.3160$ ,  $P=0.0390$ ) was  
155 observed between calf muscle strength and the mean myofiber area (**Figure 1E**). These findings reveal a  
156 clear deterioration in muscle function in PAD patients with CKD.

157

158 **Calf muscle mitochondrial function is negatively impacted by CKD, but not PAD alone.** High-resolution  
159 respirometry and fluorescence spectroscopy were used to assess muscle mitochondrial function in  
160 freshly permeabilized muscle fiber bundles using a creatine kinase clamp to perform a ‘mitochondrial  
161 stress test’ across a range of physiologically relevant energy demands (**Figure 2A**). Oxygen consumption  
162 ( $JO_2$ ) was lower in patients with CKD and PAD+CKD, but nearly identical in patients with only PAD and  
163 control participants (**Figure 2B**). Quantification of the slope of oxygen consumption vs. energy demand  
164 ( $\Delta G_{ATP}$ ), termed OXPHOS conductance, represents the sensitivity of the mitochondrial system to respond  
165 to increases in energy demand. In this case, a higher OXPHOS conductance is interpreted as better  
166 mitochondrial function. OXPHOS conductance was not different between controls and PAD patients with  
167 normal kidney function ( $P=0.97$ ), however CKD patients without PAD and PAD+CKD patients had

168 significantly lower OXPHOS conductance compared to controls ( $P=0.0123$  and  $P=0.0054$  respectively).  
169 PAD+CKD patients had significantly lower OXPHOS conductance than PAD patients without CKD (**Figure**  
170 **2C**). Citrate synthase activity, a biomarker of mitochondrial content in skeletal muscle, was not  
171 significantly lower in CKD ( $P=0.095$ ) and PAD+CKD ( $P=0.63$ ) groups compared to controls (**Figure 2D**).  
172 Mitochondrial  $H_2O_2$  emission was not significantly different between groups across the levels of energy  
173 demand (**Figure 2E**) or without energy demand (**Figure 2F**) when fueled by  
174 pyruvate/malate/octanoylcarnitine. When fueled with succinate in the absence of energy demand with  
175 or without inhibitors of the matrix antioxidant systems, PAD+CKD muscles had lower mitochondrial  $H_2O_2$   
176 emission than controls (**Figure 2G**). Succinate dehydrogenase (SDH) enzyme activity assessed  
177 histochemically on thin sections of muscle showed a lower SDH activity in CKD and PAD+CKD groups  
178 (**Figure 2H**).

179  
180 **CKD significantly alters the plasma metabolome.** Next, we performed targeted metabolomics to  
181 quantify the absolute abundance of known uremic toxins including 3-indoxyl sulfate, p-cresol sulfate  
182 (pCS), 4-ethylphenyl sulfate (4-EPS), 3-indolelactic acid, 3-indolepropionic acid, kynurenine (L-Kyn),  
183 tryptophan (Trp), and the L-Kyn/Trp ratio in plasma of this cohort. As expected, CKD and PAD+CKD  
184 groups had significantly higher levels of all these uremic toxins (**Figure 3A**). No differences were found  
185 between controls and patients with PAD only. We also performed global untargeted metabolomics on  
186 the cohort which resulted in identification of 1557 metabolites/biochemicals, 1277 of which were  
187 identified in the compound library and 277 with unknown identity (**Figure 3B**). Principal component  
188 analysis revealed two relatively distinct clusters which separate the patients with and without CKD  
189 (**Figure 3C**). Compared to controls, patients with PAD had relatively similar plasma metabolomes with 99  
190 differentially abundant metabolites (46 up and 53 down). In contrast, patients with CKD had 763  
191 differentially abundant metabolites compared to controls (623 up and 140 down). Consistent with these  
192 findings, PAD+CKD patients had 578 differentially abundant metabolites (521 up and 57 down)  
193 compared to PAD patients. A heatmap with hierarchical clustering for all patients and metabolites is  
194 shown in **Figure 3D**. A Venn diagram showing the shared and distinct numbers of differentially abundant  
195 metabolites across comparisons is shown in **Figure 3E**. Pathway analysis revealed three main classes of  
196 metabolites were impacted by disease classification including “Uremic Toxins”, “Tissue Remodeling”,  
197 and Microbiome-related metabolites” (**Supplemental Figure 1**). The complete metabolomics dataset  
198 and pathway analysis can be found in Supplemental Datasets 1 and 2 respectively.

199

200 **Skeletal muscle mitochondrial function and calf muscle strength are negatively correlated with**  
201 **tryptophan-derived uremic toxins.** Previous studies have reported that tryptophan-derived uremic  
202 toxins, such as indoxyl sulfate and kynurenine, were negatively associated with muscle health and  
203 mitochondrial function<sup>23,28-31</sup>. Thus, we perform Pearson correlation analyses to determine if  
204 mitochondrial function (OXPHOS conductance) or muscle strength were related to these uremic toxins.  
205 Strikingly, kynurenine, L-Kyn/Trp ratio, and indoxyl sulfate had significant inverse correlations with both  
206 mitochondrial function (**Figure 4A**) and calf muscle strength (**Figure 4B**) in this cohort.

207

208 **Whole muscle and single nucleus RNA sequencing identifies transcriptome changes in PAD patients**  
209 **with CKD.** To understand how CKD impacts the skeletal muscle transcriptome, we performed bulk RNA  
210 sequencing on total RNA isolated from a portion of the gastrocnemius muscle biopsy of 88 patients.  
211 Gene expression was quantified for 24,871 genes. Comparing PAD to controls, 52 differentially  
212 expressed genes were detected (12 downregulated and 40 upregulated) (**Supplemental Figure 2A-D**).  
213 Comparing CKD to controls, 602 differentially expressed genes were detected (300 downregulated and  
214 302 upregulated) (**Supplemental Figure 2E-H**). Comparing patients with PAD to those with PAD+CKD,  
215 partial least squares discriminant analysis (PLS-DA) showed two distinct clusters (**Figure 5A**). Patients  
216 with PAD+CKD had 361 differentially expressed genes from patients with only PAD (189 downregulated  
217 and 172 upregulated) (**Figure 5B**). GSEA in this comparison revealed that down regulated genes were  
218 significantly enriched in pathways related to “cellular respiration” and “oxidative phosphorylation”,  
219 whereas significantly upregulated genes were enriched in pathways related to “cytoplasmic translation”,  
220 “ribosome biogenesis”, and “rRNA processing” (**Figure 5C**). Full results of the DEG and GSEA analysis for  
221 each comparison can be found in Supplemental Dataset 3.

222 Because there are many cell types within skeletal muscle, we next used single nucleus RNA  
223 sequencing to enhance the resolution of analysis of calf muscle. 61,586 nuclei were analyzed from 20  
224 PAD patients and 12 patients with PAD+CKD. Unsupervised clustering identified 14 clusters representing  
225 the major cell types expected in skeletal muscle (**Figure 5D**). Compared to PAD patients without CKD,  
226 PAD+CKD patients had fewer Type I myofiber nuclei and a higher proportion of nuclei that represented  
227 NMJ/regenerating myonuclei, fibro-adipogenic progenitor cells (FAPs), endothelial cells, and  
228 macrophages (**Figure 5E**). Top marker genes for each cell/nuclei type are shown in **Figure 5F**. DEG



229 analysis in the myofiber nuclei populations (**Figure 5G,H**) revealed a significant number of differentially  
230 expressed genes within each cluster, however Type I myofiber nuclei had the largest number of DEGs.  
231 With knowledge that bulk RNAseq GSEA analysis identified mitochondria as a downregulated biological  
232 process, we generated a mitochondrial gene expression score which represents the overall  
233 mitochondrial gene expression. This analysis confirmed all myonuclei populations in PAD+CKD muscles  
234 displayed a mitochondrial deficiency, although Type I myofiber nuclei appeared to be most affected  
235 (**Figure 5I**). GSEA analysis from myonuclei had common pathways related to “aerobic respiration” in the  
236 downregulated DEGs (**Figure 5J**). Additional DEG, GSEA, and top marker genes for other cell types can be  
237 found in Supplemental Dataset 4.

238

239 **Fibro-adipogenic progenitor (FAPs) cells are uniquely remodeled in muscle from patients with PAD**  
240 **and CKD.** Next, we investigated how CKD impact FAPs, a resident mesenchymal stem cell population  
241 that has been shown to be critical for muscle regeneration, were impacted by CKD in patients with PAD.  
242 Subclustering of FAPs revealed eight distinct cell populations including pro-fibrotic, adipogenic, and  
243 MME+ clusters<sup>32</sup> (**Figure 6A**). PAD patients with CKD had a higher abundance of adipocyte/adipogenic  
244 FAPs (16% vs. 5.6%) and a unique population of ADAM12<sup>+</sup> FAPs that was only present in PAD+CKD  
245 (**Figure 6B**). We used the Palantir algorithm<sup>33</sup> to characterize differences in cell fate between PAD and  
246 PAD+CKD FAPs. In patients with only PAD, a single terminate state representing the low abundance  
247 adipocyte lineage was observed, whereas two clear terminal states were seen in PAD+CKD FAPs  
248 (adipocyte and MME<sup>+</sup>) along with a substantially higher differentiation potential in other populations  
249 compared with FAPs from PAD patients (**Figure 6C**). Trajectory inference uncovered an additional  
250 pathway for FAP differentiation in patients with PAD+CKD producing the ADAM12<sup>+</sup> population (**Figure**  
251 **6D**). Normalized gene expression showed the ADAM12<sup>+</sup> FAP population was enriched for myokines IL6  
252 and IGF1, whereas the pro-fibrotic FAPs displayed high expression of TGFB1 and COL1A1 (**Figure 6E**).  
253 Expression of branch-specific genes along pseudotime are shown in **Figure 6F**. Other notable cell types  
254 that displayed significant transcriptome and population differences in PAD+CKD included macrophages  
255 (**Supplemental Figure 3**) and endothelial cells (**Supplemental Figure 4**).

256

257 **CKD influences intercellular communication in calf muscle from patients with PAD.** To explore how the  
258 presence of CKD influences intercellular communication, we employed CellChat<sup>34</sup> to assess inferred

259 ligand-receptor interactions. Circle plots depicting the global intercellular communication are shown in  
260 **Figure 7A**, where the line width represents the communication strength. While the number of  
261 interactions was lower in PAD+CKD compared to PAD (2920 vs. 3552), the strength of those interactions  
262 was greater (**Figure 7B**). Comparisons of the major ‘senders’ and ‘receivers’ identified FAPs and  
263 adipocytes as the primary ‘senders’ whereas vascular populations including endothelial, lymphatic  
264 endothelial, and smooth muscle/pericyte cells were determined to be the major ‘receivers’ (**Figure 7C**).  
265 Significant signaling pathways between PAD and PAD+CKD were identified according to variations in  
266 information flow within inferred signaling networks (**Figure 7D**)

267

## 268 **DISCUSSION**

269 Patients with PAD often present with one or more comorbid conditions that worsen ischemic pathology  
270 and increase the risk of an adverse limb event. Recent studies have clearly demonstrated that CKD may  
271 be one of the strongest risk factors for poor outcomes in PAD<sup>11,35</sup>. In this cross-sectional study, we  
272 leveraged state-of-the-art multiomic analyses and mitochondrial and muscle function assessments to  
273 dissect how CKD impacts calf muscle pathophysiology in patients with PAD. Compared to non-PAD  
274 control with normal kidney function, patients with only PAD, patients with only CKD, and patients with  
275 both PAD and CKD had significantly weaker calf muscles and muscle fiber areas (Figure 1). Compared to  
276 patients with PAD, those with PAD and CKD were also significantly weaker and had smaller muscle fiber  
277 areas demonstrating that CKD exacerbates the ischemic myopathy in PAD. Skeletal muscle  
278 mitochondrial function was significantly impaired in patients with CKD only and those with PAD and CKD  
279 (Figure 2). Interestingly, no differences were observed between patients with PAD and the non-PAD  
280 controls. A significant negative correlation was found between the levels of indoxyl sulfate, L-  
281 Kynurenine, or the L-Kyn/Trp ratio and both mitochondrial function and muscle strength (Figure 4). This  
282 observation agrees with previous studies that reported similar associations in rodents with and without  
283 CKD<sup>23,28-30</sup>, implicating uremic toxins as strong drivers of muscle impairment in CKD. These findings also  
284 agree with those of preclinical studies in which limb function of animals with CKD subjected to hindlimb  
285 ischemia was impaired compared to animals with normal kidney function subjected to hindlimb  
286 ischemia<sup>11,30,36-38</sup>. Mechanistically, recent studies have shown that the aryl hydrocarbon receptor is  
287 required for tryptophan-derived uremic toxins to impair skeletal muscle function and ischemic  
288 angiogenesis<sup>11,30,38</sup>. Beyond uremic toxins, tobacco smoking products also contain ligands that activate  
289 the aryl hydrocarbon receptor in skeletal muscle<sup>39,40</sup>, namely 2,3,7,8-Tetrachlorodibenzodioxin (known

290 as TCDD), and smoking is considered the strongest risk factor for PAD suggesting this pathway could  
291 have a much broader impact of calf muscle pathophysiology in patients with PAD. In totality, these  
292 findings suggest that CKD induces muscle mitochondrial dysfunction in patients with and without PAD,  
293 potentially through mechanisms involving uremic toxins like indoxyl sulfate and kynurenines that  
294 activate the aryl hydrocarbon receptor.

295  
296 Calf muscle mitochondrial OXPHOS was ~40% lower in patients with CKD than those without (Figure 2).  
297 This profound impact of CKD on skeletal muscle mitochondrial function and content aligns with previous  
298 studies<sup>21,24,41-43</sup>. In contrast, there were no differences between non-PAD controls and patients with PAD  
299 that had normal kidney function. This lack of difference in mitochondrial respiratory function is  
300 consistent with some previous studies<sup>44-46</sup>, but not all<sup>47-50</sup>, that used similar methodologies. The lack of  
301 agreement across these studies may be due to modest sample sizes and differences in patient  
302 characteristics. Nonetheless, there is accumulating evidence that markers of mitochondrial content  
303 (mtDNA copy number, electron transport system complex abundance, citrate synthase activity, etc.) are  
304 increased in the calf muscle of patients with PAD<sup>17,51,52</sup>. This compensatory response is likely related to  
305 the hypoxia-induced energetic stress response that occurs within the calf muscles of PAD<sup>17</sup>. The striking  
306 impact of CKD on calf muscle mitochondrial health was also supported by the down regulation of  
307 mitochondrial gene expression observed in both bulk and single nucleus RNA sequencing analyses  
308 comparing PAD and PAD+CKD groups (Figure 5). In both diseases calf muscle mitochondrial function  
309 correlates with walking performance<sup>24,52,53</sup>. Further investigation is needed to determine whether  
310 interventions that improve or optimize calf muscle mitochondrial function can lead to improvements in  
311 walking performance in these patients.

312  
313 Calf muscle from patients with PAD and CKD displayed a unique remodeling of a resident mesenchymal  
314 stem population called fibro-adipogenic progenitor cells (FAPs). These resident multipotent stem cells  
315 are located within the muscle interstitium where they have a heavy presence surrounding blood vessels.  
316 They have numerous differentiation paths with the two main fates being adipocytes or myofibroblasts<sup>54</sup>.  
317 Compared to PAD patients with normal kidney function, those with PAD and CKD had ~2.5-fold increase  
318 in adipocytes according to snRNAseq results. This accumulation of intramuscular adipose tissue is a form  
319 of myosteatosis which has been shown to impair muscle function<sup>55,56</sup> and regeneration from injury<sup>57-59</sup>.

320 This phenotype has been observed independently in CKD<sup>60</sup> and PAD<sup>61</sup>. Considering that muscle function  
321 is strongly associated with mortality in PAD<sup>13,15</sup> and CKD<sup>62</sup>, further studies are needed to determine if  
322 therapies that prevent or mitigate intramuscular adipose tissue in these conditions can improve muscle  
323 function and lower mortality risk.

324

325 Plasma metabolomics analyses revealed the wide-ranging impact on the plasma metabolome in patients  
326 with CKD (>500 differentially abundant biochemicals). In contrast, we found relatively few metabolites  
327 (99) that were differentially abundant between non-PAD controls and PAD patients. Only a few studies  
328 have examined the plasma metabolomes in patients with PAD<sup>11,63-65</sup>, with the majority of studies  
329 reporting associations between amino acid metabolites, namely kynurenine and tryptophan, as well as  
330 indoles, and the risk of developing PAD or having adverse limb events<sup>11,64,65</sup>. The link between these  
331 uremic toxins and PAD risk may be indicative of the incidence of renal dysfunction in those study  
332 populations despite some studies excluding patients with diagnosed kidney disease. Alternatively, the  
333 source of kynurenines and indoles could be related to levels of systemic inflammation or dysregulation  
334 of the gut microbiome<sup>66-68</sup>, both areas that have been underexplored in PAD. The highly overlapping  
335 plasma metabolomes between the non-PAD controls and patients with PAD may also be indicative of  
336 how well these groups were matched for co-morbid conditions, risk factors, and medication usage  
337 (Table 1). Additionally, the plasma metabolome in PAD is not likely to match the complex  
338 microenvironment within the affected limb where local metabolite alterations are presumed to be much  
339 greater than those reflected from a systemic plasma sample. Local sample collection from the diseased  
340 limb followed by subsequent metabolomic analyses could reveal the full impact of limb ischemia on  
341 metabolite exchange in tissues below of the occlusive lesion.

342

343 Given that our cohort of patients were restricted to moderate CKD (Stage 3b-4) and moderate-severe  
344 PAD (Rutherford Stage 3-5), our analyses may not be representative of the full spectrum of either  
345 disease. However, this design was chosen to enable deep phenotyping and multiomic analyses across  
346 the four groups. Additional studies should be performed to evaluate the reported relationships across  
347 the spectrum of both PAD and CKD. Although this patient cohort contained 39% female participants, we  
348 have not performed sex comparisons due to the relatively small sample sizes within each group for such  
349 a comparison. Future analyses of these data could be performed to begin understanding how biological

350 sex may alter the impact of CKD on PAD pathobiology. Additionally, while the control group was  
351 relatively well matched for clinical and physical characteristics, there were some comorbid conditions  
352 that were more prevalent in the PAD and CKD groups including hypertension and diabetes. It is  
353 important to note that these two conditions are among the strongest risk factors for developing CKD.  
354 This was a cross-sectional study design and longitudinal analyses were not performed. Thus, analyses  
355 exploring how specific outcomes change across time and whether they impact adverse limb events,  
356 morbidity, or mortality risk could not be performed. Despite these limitations, this study provides a  
357 robust and in-depth analysis of the skeletal myopathy in patients with PAD and CKD using physiological  
358 testing and multiomic analyses which identify pathways and processes that may have potential for  
359 interventional approaches that have promise to improve muscle function in these patients.

360

## 361 **CONCLUSIONS**

362 This study demonstrates that chronic kidney disease significantly worsens the ischemic limb myopathy  
363 in patients with PAD evidenced by lower calf muscle strength, muscle fiber sizes, and mitochondrial  
364 function. Multiomic analyses of calf muscle revealed a striking deficiency in myonuclear gene expression  
365 related to mitochondria and protein translation specifically in patients with both PAD and CKD,  
366 compared to those with only PAD. The significant correlation between plasma uremic toxin levels and  
367 both calf muscle strength and mitochondrial function suggests that therapeutic strategies aimed at  
368 reducing uremic toxins may hold promise for improving muscle health in patients with CKD.

369

370 **Sources of Funding:** This study was supported by National Institutes of Health (NIH) grants R01-  
371 HL149704 and HL171050 (T.E.R.). S.T.S. was supported by NIH grant R01HL148597. S.A.B. was supported  
372 by NIH grant R01DK119274. K.K. was supported by the American Heart Association grant POST903198.  
373 T.T. was supported by NIH grant F31-DK128920. V.R.P. was supported by the American Heart  
374 Association grant 24PRE1193999. C.P. was supported by the American Heart Association grant  
375 24PRE1196311.

376

377 **Disclosures:** None.

378

379 **Supplemental Material:**

380 Expanded Materials and Methods

381 Supplemental Figures 1-4

382 Supplemental Dataset 1 (metabolomics).XLSX

383 Supplemental Dataset 2 (metabolomics pathway).XLSX

384 Supplemental Dataset 3 (bulk RNA).xlsx

385 Supplemental Dataset 4 (snRNA).xlsx

386

387 **References**

- 388 1. Ostchega Y, Paulose-Ram R, Dillon CF, Gu Q, Hughes JP. Prevalence of peripheral arterial  
389 disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition  
390 Examination Survey 1999-2004. *J Am Geriatr Soc.* 2007;55:583-589. doi: 10.1111/j.1532-  
391 5415.2007.01123.x
- 392 2. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE,  
393 Sampson UK, Williams LJ, Mensah GA, et al. Comparison of global estimates of prevalence and  
394 risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis.  
395 *Lancet.* 2013;382:1329-1340. doi: 10.1016/S0140-6736(13)61249-0
- 396 3. Heideman PP, Rajebi MR, McKusick MA, Bjarnason H, Oderich GS, Friese JL, Fleming MD,  
397 Stockland AH, Harmsen WS, Mandrekar J, et al. Impact of Chronic Kidney Disease on Clinical  
398 Outcomes of Endovascular Treatment for Femoropopliteal Arterial Disease. *J Vasc Interv Radiol.*  
399 2016;27:1204-1214. doi: 10.1016/j.jvir.2016.04.036
- 400 4. Kaminski MR, Raspovic A, McMahon LP, Lambert KA, Erbas B, Mount PF, Kerr PG, Landorf  
401 KB. Factors associated with foot ulceration and amputation in adults on dialysis: a cross-sectional  
402 observational study. *BMC Nephrol.* 2017;18:293. doi: 10.1186/s12882-017-0711-6
- 403 5. O'Hare AM, Sidawy AN, Feinglass J, Merine KM, Daley J, Khuri S, Henderson WG, Johansen  
404 KL. Influence of renal insufficiency on limb loss and mortality after initial lower extremity  
405 surgical revascularization. *J Vasc Surg.* 2004;39:709-716. doi: 10.1016/j.jvs.2003.11.038
- 406 6. Lacroix P, Aboyans V, Desormais I, Kowalsky T, Cambou JP, Constans J, Bura Riviere A,  
407 investigators C. Chronic kidney disease and the short-term risk of mortality and amputation in  
408 patients hospitalized for peripheral artery disease. *J Vasc Surg.* 2013;58:966-971. doi:  
409 10.1016/j.jvs.2013.04.007

- 410 7. O'Hare AM, Bertenthal D, Shlipak MG, Sen S, Chren MM. Impact of renal insufficiency on  
411 mortality in advanced lower extremity peripheral arterial disease. *Journal of the American Society*  
412 *of Nephrology : JASN*. 2005;16:514-519. doi: 10.1681/ASN.2004050409
- 413 8. Pasqualini L, Schillaci G, Pirro M, Vaudo G, Siepi D, Innocente S, Ciuffetti G, Mannarino E.  
414 Renal dysfunction predicts long-term mortality in patients with lower extremity arterial disease. *J*  
415 *Intern Med*. 2007;262:668-677. doi: 10.1111/j.1365-2796.2007.01863.x
- 416 9. Liew YP, Bartholomew JR, Demirjian S, Michaels J, Schreiber MJ, Jr. Combined effect of  
417 chronic kidney disease and peripheral arterial disease on all-cause mortality in a high-risk  
418 population. *Clin J Am Soc Nephrol*. 2008;3:1084-1089. doi: 10.2215/CJN.04411007
- 419 10. Patel VI, Mukhopadhyay S, Guest JM, Conrad MF, Watkins MT, Kwolek CJ, LaMuraglia GM,  
420 Cambria RP. Impact of severe chronic kidney disease on outcomes of infrainguinal peripheral  
421 arterial intervention. *J Vasc Surg*. 2014;59:368-375. doi: 10.1016/j.jvs.2013.09.006
- 422 11. Arinze NV, Yin WQ, Lotfollahzadeh S, Napoleon MA, Richards S, Walker JA, Belghasem M,  
423 Ravid JD, Kamel MH, Whelan SA, et al. Tryptophan metabolites suppress the Wnt pathway and  
424 promote adverse limb events in chronic kidney disease. *J Clin Invest*. 2022;132. doi: ARTN  
425 e142260  
426 10.1172/JCI142260
- 427 12. McDermott MM, Criqui MH, Greenland P, Guralnik JM, Liu K, Pearce WH, Taylor L, Chau CL,  
428 Celic L, Woolley C, et al. Leg strength in peripheral arterial disease: Associations with disease  
429 severity and lower-extremity performance. *Journal of Vascular Surgery*. 2004;39:523-530. doi:  
430 10.1016/j.jvs.2003.08.038
- 431 13. Singh N, Liu K, Tian L, Criqui MH, Guralnik JM, Ferrucci L, Liao Y, McDermott MM. Leg  
432 strength predicts mortality in men but not in women with peripheral arterial disease. *J Vasc Surg*.  
433 2010;52:624-631. doi: 10.1016/j.jvs.2010.03.066
- 434 14. Garg PK, Liu K, Ferrucci L, Guralnik JM, Criqui MH, Tian L, Sufit R, Nishida T, Tao HM, Liao  
435 YH, et al. Lower Extremity Nerve Function, Calf Skeletal Muscle Characteristics, and Functional  
436 Performance in Peripheral Arterial Disease. *J Am Geriatr Soc*. 2011;59:1855-1863. doi:  
437 10.1111/j.1532-5415.2011.03600.x
- 438 15. McDermott MM, Liu K, Tian L, Guralnik JM, Criqui MH, Liao Y, Ferrucci L. Calf muscle  
439 characteristics, strength measures, and mortality in peripheral arterial disease: a longitudinal  
440 study. *J Am Coll Cardiol*. 2012;59:1159-1167. doi: 10.1016/j.jacc.2011.12.019
- 441 16. McDermott MM, Ferrucci L, Gonzalez-Freire M, Kosmac K, Leeuwenburgh C, Peterson CA,  
442 Saini S, Sufit R. Skeletal Muscle Pathology in Peripheral Artery Disease A Brief Review.  
443 *Arterioscl Throm Vas*. 2020;40:2577-2585. doi: 10.1161/Atvbaha.120.313831
- 444 17. Ferrucci L, Candia J, Ubaida-Mohien C, Lyaskov A, Banskota N, Leeuwenburgh C, Wohlgemuth  
445 S, Guralnik JM, Kaileh M, Zhang D, et al. Transcriptomic and Proteomic of Gastrocnemius

- 446 Muscle in Peripheral Artery Disease. *Circulation research*. 2023. doi:  
447 10.1161/CIRCRESAHA.122.322325
- 448 18. John SG, Sigrist MK, Taal MW, McIntyre CW. Natural history of skeletal muscle mass changes  
449 in chronic kidney disease stage 4 and 5 patients: an observational study. *PLoS One*.  
450 2013;8:e65372. doi: 10.1371/journal.pone.0065372
- 451 19. Tamaki M, Miyashita K, Wakino S, Mitsuishi M, Hayashi K, Itoh H. Chronic kidney disease  
452 reduces muscle mitochondria and exercise endurance and its exacerbation by dietary protein  
453 through inactivation of pyruvate dehydrogenase. *Kidney Int*. 2014;85:1330-1339. doi:  
454 10.1038/ki.2013.473
- 455 20. Yokoi H, Yanagita M. Decrease of muscle volume in chronic kidney disease: the role of  
456 mitochondria in skeletal muscle. *Kidney Int*. 2014;85:1258-1260. doi: 10.1038/ki.2013.539
- 457 21. Gamboa JL, Roshanravan B, Towse T, Keller CA, Falck AM, Yu C, Frontera WR, Brown NJ,  
458 Ikizler TA. Skeletal Muscle Mitochondrial Dysfunction Is Present in Patients with CKD before  
459 Initiation of Maintenance Hemodialysis. *Clin J Am Soc Nephro*. 2020;15:926-936. doi:  
460 10.2215/Cjn.10320819
- 461 22. Brightwell CR, Kulkarni AS, Paredes W, Zhang KH, Perkins JB, Gatlin KJ, Custodio M, Farooq  
462 H, Zaidi B, Pai RM, et al. Muscle fibrosis and maladaptation occur progressively in CKD and are  
463 rescued by dialysis. *Jci Insight*. 2021;6. doi: ARTN e150112  
464 10.1172/jci.insight.150112
- 465 23. Thome T, Vugman NA, Stone LE, Wimberly K, Scali ST, Ryan TE. A tryptophan-derived uremic  
466 metabolite-Ahr-Pdk4 axis governs skeletal muscle mitochondrial energetics in chronic kidney  
467 disease. *JCI Insight*. 2024. doi: 10.1172/jci.insight.178372
- 468 24. Kestenbaum B, Gamboa J, Liu S, Ali AS, Shankland E, Jue T, Giulivi C, Smith LR, Himmelfarb  
469 J, de Boer IH, et al. Impaired skeletal muscle mitochondrial bioenergetics and physical  
470 performance in chronic kidney disease. *JCI Insight*. 2020;5. doi: 10.1172/jci.insight.133289
- 471 25. McDermott MM, Liu K, Ferrucci L, Tian L, Guralnik JM, Liao Y, Criqui MH. Decline in  
472 functional performance predicts later increased mobility loss and mortality in peripheral arterial  
473 disease. *J Am Coll Cardiol*. 2011;57:962-970. doi: 10.1016/j.jacc.2010.09.053
- 474 26. Jain A, Liu K, Ferrucci L, Criqui MH, Tian L, Guralnik JM, Tao H, McDermott MM. Declining  
475 walking impairment questionnaire scores are associated with subsequent increased mortality in  
476 peripheral artery disease. *J Am Coll Cardiol*. 2013;61:1820-1829. doi: 10.1016/j.jacc.2013.01.060
- 477 27. Leeper NJ, Myers J, Zhou M, Nead KT, Syed A, Kojima Y, Caceres RD, Cooke JP. Exercise  
478 capacity is the strongest predictor of mortality in patients with peripheral arterial disease. *J Vasc*  
479 *Surg*. 2013;57:728-733. doi: 10.1016/j.jvs.2012.07.051



- 480 28. Thome T, Kumar RA, Burke SK, Khattri RB, Salyers ZR, Kelley RC, Coleman MD, Christou  
481 DD, Hepple RT, Scali ST, et al. Impaired muscle mitochondrial energetics is associated with  
482 uremic metabolite accumulation in chronic kidney disease. *Jci Insight*. 2021;6.
- 483 29. Palzkill VR, Thome T, Murillo AL, Khattri RB, Ryan TE. Increasing plasma L-kynurenine  
484 impairs mitochondrial oxidative phosphorylation prior to the development of atrophy in murine  
485 skeletal muscle: A pilot study. *Frontiers in physiology*. 2022;13. doi: ARTN 992413  
486 10.3389/fphys.2022.992413
- 487 30. Balestrieri N, Palzkill V, Pass C, Tan J, Salyers ZR, Moparthy C, Murillo A, Kim K, Thome T,  
488 Yang Q, et al. Activation of the Aryl Hydrocarbon Receptor in Muscle Exacerbates Ischemic  
489 Pathology in Chronic Kidney Disease. *Circulation research*. 2023;133:158-176. doi:  
490 10.1161/CIRCRESAHA.123.322875
- 491 31. Hetherington-Rauth M, Johnson E, Migliavacca E, Parimi N, Langsetmo L, Hepple RT,  
492 Grzywinski Y, Corthesy J, Ryan TE, Ferrucci L, et al. Nutrient metabolites associated with low  
493 D3Cr muscle mass, strength, and physical performance in older men. *J Gerontol A Biol Sci Med*  
494 *Sci*. 2023. doi: 10.1093/gerona/glad217
- 495 32. Fitzgerald G, Turiel G, Gorski T, Soro-Arnaiz I, Zhang J, Casartelli NC, Masschelein E,  
496 Maffiuletti NA, Sutter R, Leunig M, et al. MME+ fibro-adipogenic progenitors are the dominant  
497 adipogenic population during fatty infiltration in human skeletal muscle. *Commun Biol*. 2023;6.  
498 doi: ARTN 111  
499 10.1038/s42003-023-04504-y
- 500 33. Setty M, Kiseliovas V, Levine J, Gayoso A, Mazutis L, Pe'er D. Characterization of cell fate  
501 probabilities in single-cell data with Palantir. *Nature biotechnology*. 2019;37:451-460. doi:  
502 10.1038/s41587-019-0068-4
- 503 34. Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan CH, Myung P, Plikus MV, Nie Q.  
504 Inference and analysis of cell-cell communication using CellChat. *Nat Commun*. 2021;12:1088.  
505 doi: 10.1038/s41467-021-21246-9
- 506 35. Amlani V, Ludwigs K, Rawshani A, Thuresson M, Falkenberg M, Smidfelt K, Nordanstig J.  
507 Major Adverse Limb Events in Patients Undergoing Revascularisation for Lower Limb  
508 Peripheral Arterial Disease: A Nationwide Observational Study( bigstar). *European journal of*  
509 *vascular and endovascular surgery : the official journal of the European Society for Vascular*  
510 *Surgery*. 2024. doi: 10.1016/j.ejvs.2024.07.041
- 511 36. Jacobi J, Porst M, Cordasic N, Namer B, Schmieder RE, Eckardt KU, Hilgers KF. Subtotal  
512 nephrectomy impairs ischemia-induced angiogenesis and hindlimb re-perfusion in rats. *Kidney*  
513 *Int*. 2006;69:2013-2021. doi: 10.1038/sj.ki.5000448
- 514 37. Berru FN, Gray SE, Thome T, Kumar RA, Salyers ZR, Coleman M, Dennis L, O'Malley K,  
515 Ferreira LF, Berceci SA, et al. Chronic kidney disease exacerbates ischemic limb myopathy in

- 516 mice via altered mitochondrial energetics. *Sci Rep.* 2019;9:15547. doi: 10.1038/s41598-019-  
517 52107-7
- 518 38. Palzkill VR, Tan J, Yang Q, Morcos J, Laitano O, Ryan TE. Deletion of the aryl hydrocarbon  
519 receptor in endothelial cells improves ischemic angiogenesis in chronic kidney disease. *Am J*  
520 *Physiol Heart Circ Physiol.* 2024;326:H44-H60. doi: 10.1152/ajpheart.00530.2023
- 521 39. Thome T, Miguez K, Willms AJ, Burke SK, Chandran V, de Souza AR, Fitzgerald LF, Bagloli  
522 C, Anagnostou ME, Bourbeau J, et al. Chronic aryl hydrocarbon receptor activity phenocopies  
523 smoking-induced skeletal muscle impairment. *J Cachexia Sarcopenia Muscle.* 2022;13:589-604.  
524 doi: 10.1002/jcsm.12826
- 525 40. Fitzgerald LF, Lackey J, Moussa A, Shah SV, Castellanos AM, Khan S, Schonk M, Thome T,  
526 Salyers ZR, Jakkidi N, et al. Chronic aryl hydrocarbon receptor activity impairs muscle  
527 mitochondrial function with tobacco smoking. *J Cachexia Sarcopenia Muscle.* 2024;15:646-659.  
528 doi: 10.1002/jcsm.13439
- 529 41. Bittel DC, Bittel AJ, Varadhachary AS, Pietka T, Sinacore DR. Deficits in the Skeletal Muscle  
530 Transcriptome and Mitochondrial Coupling in Progressive Diabetes-Induced CKD Relate to  
531 Functional Decline. *Diabetes.* 2021;70:1130-1144. doi: 10.2337/db20-0688
- 532 42. Xu CQ, Kasimumali A, Guo XJ, Lu RH, Xie KW, Zhu ML, Qian YY, Chen XH, Pang HH,  
533 Wang Q, et al. Reduction of mitochondria and up regulation of pyruvate dehydrogenase kinase 4  
534 of skeletal muscle in patients with chronic kidney disease. *Nephrology.* 2020;25:230-238. doi:  
535 10.1111/nep.13606
- 536 43. Watson EL, Baker LA, Wilkinson TJ, Gould DW, Graham-Brown MPM, Major RW, Ashford  
537 RU, Philp A, Smith AC. Reductions in skeletal muscle mitochondrial mass are not restored  
538 following exercise training in patients with chronic kidney disease. *Faseb J.* 2020;34:1755-1767.  
539 doi: 10.1096/fj.201901936RR
- 540 44. Ryan TE, Yamaguchi DJ, Schmidt CA, Zeczycki TN, Shaikh SR, Brophy P, Green TD, Tarpey  
541 MD, Karnekar R, Goldberg EJ, et al. Extensive skeletal muscle cell mitochondriopathy  
542 distinguishes critical limb ischemia patients from claudicants. *JCI Insight.* 2018;3. doi:  
543 10.1172/jci.insight.123235
- 544 45. Hart CR, Layec G, Trinity JD, Kwon OS, Zhao J, Reese VR, Gifford JR, Richardson RS.  
545 Increased skeletal muscle mitochondrial free radical production in peripheral arterial disease  
546 despite preserved mitochondrial respiratory capacity. *Exp Physiol.* 2018. doi: 10.1113/EP086905
- 547 46. Hart CR, Layec G, Trinity JD, Le Fur Y, Gifford JR, Clifton HL, Richardson RS. Oxygen  
548 availability and skeletal muscle oxidative capacity in patients with peripheral artery disease:  
549 implications from in vivo and in vitro assessments. *Am J Physiol-Heart C.* 2018;315:H897-H909.  
550 doi: 10.1152/ajpheart.00641.2017
- 551 47. Park SY, Pekas EJ, Anderson CP, Kambis TN, Mishra PK, Schieber MN, Wooden TK,  
552 Thompson JR, Kim KS, Pipinos, II. Impaired microcirculatory function, mitochondrial

- 553 respiration, and oxygen utilization in skeletal muscle of claudicating patients with peripheral  
554 artery disease. *Am J Physiol Heart Circ Physiol*. 2022;322:H867-H879. doi:  
555 10.1152/ajpheart.00690.2021
- 556 48. Lindegard Pedersen B, Baekgaard N, Quistorff B. Mitochondrial dysfunction in calf muscles of  
557 patients with combined peripheral arterial disease and diabetes type 2. *International Angiology*.  
558 2017;36:482-495. doi: 10.23736/S0392-9590.17.03824-X
- 559 49. Pipinos, II, Sharov VG, Shepard AD, Anagnostopoulos PV, Katsamouris A, Todor A, Filis KA,  
560 Sabbah HN. Abnormal mitochondrial respiration in skeletal muscle in patients with peripheral  
561 arterial disease. *J Vasc Surg*. 2003;38:827-832.
- 562 50. Pipinos, II, Judge AR, Zhu Z, Selsby JT, Swanson SA, Johanning JM, Baxter BT, Lynch TG,  
563 Dodd SL. Mitochondrial defects and oxidative damage in patients with peripheral arterial disease.  
564 *Free Radic Biol Med*. 2006;41:262-269. doi: 10.1016/j.freeradbiomed.2006.04.003
- 565 51. Picca A, Wohlgemuth SE, McDermott MM, Saini SK, Dayanidhi S, Zhang D, Xu S, Kosmac K,  
566 Tian L, Ferrucci L, et al. Mitochondrial Complex Abundance, Mitophagy Proteins, and Physical  
567 Performance in People With and Without Peripheral Artery Disease. *Journal of the American*  
568 *Heart Association*. 2023;12:e027088. doi: 10.1161/JAHA.122.027088
- 569 52. McDermott MM, Peterson CA, Sufit R, Ferrucci L, Guralnik JM, Kibbe MR, Polonsky TS, Tian  
570 L, Criqui MH, Zhao L, et al. Peripheral artery disease, calf skeletal muscle mitochondrial DNA  
571 copy number, and functional performance. *Vasc Med*. 2018;1358863X18765667. doi:  
572 10.1177/1358863X18765667
- 573 53. Gonzalez-Freire M, Moore AZ, Peterson CA, Kosmac K, McDermott MM, Sufit RL, Guralnik  
574 JM, Polonsky T, Tian L, Kibbe MR, et al. Associations of Peripheral Artery Disease With Calf  
575 Skeletal Muscle Mitochondrial DNA Heteroplasmy. *Journal of the American Heart Association*.  
576 2020;9:e015197. doi: 10.1161/JAHA.119.015197
- 577 54. Flores-Opazo M, Kopinke D, Helmbacher F, Fernandez-Verdejo R, Tunon-Suarez M, Lynch GS,  
578 Contreras O. Fibro-adipogenic progenitors in physiological adipogenesis and intermuscular  
579 adipose tissue remodeling. *Mol Aspects Med*. 2024;97:101277. doi: 10.1016/j.mam.2024.101277
- 580 55. Correa-de-Araujo R, Addison O, Miljkovic I, Goodpaster BH, Bergman BC, Clark RV, Elena  
581 JW, Esser KA, Ferrucci L, Harris-Love MO, et al. Myosteatosis in the Context of Skeletal Muscle  
582 Function Deficit: An Interdisciplinary Workshop at the National Institute on Aging. *Frontiers in*  
583 *physiology*. 2020;11. doi: ARTN 963  
584 10.3389/fphys.2020.00963
- 585 56. Blitz NK, Collins KH, Shen KC, Schwartz K, Harris CA, Meyer GA. Infiltration of intramuscular  
586 adipose tissue impairs skeletal muscle contraction. *J Physiol-London*. 2020;598:2669-2683. doi:  
587 10.1113/Jp279595

- 588 57. Norris AM, Appu AB, Johnson CD, Zhou LY, McKellar DW, Renault MA, Hammers D,  
589 Cosgrove BD, Kopinke D. Hedgehog signaling via its ligand DHH acts as cell fate determinant  
590 during skeletal muscle regeneration. *Nature Communications*. 2023;14. doi: ARTN 3766  
591 10.1038/s41467-023-39506-1
- 592 58. Norris AM, Fierman KE, Campbell J, Pitale R, Shahraj M, Kopinke D. Studying intramuscular  
593 fat deposition and muscle regeneration: insights from a comparative analysis of mouse strains,  
594 injury models, and sex differences. *Skelet Muscle*. 2024;14:12. doi: 10.1186/s13395-024-00344-4
- 595 59. Joe AWB, Yi L, Natarajan A, Le Grand F, So L, Wang J, Rudnicki MA, Rossi FMV. Muscle  
596 injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. *Nature cell  
597 biology*. 2010;12:153-U144. doi: 10.1038/ncb2015
- 598 60. Cheema B, Abas H, Smith B, O'Sullivan AJ, Chan M, Patwardhan A, Kelly J, Gillin A, Pang G,  
599 Lloyd B, et al. Investigation of skeletal muscle quantity and quality in end-stage renal disease.  
600 *Nephrology (Carlton)*. 2010;15:454-463. doi: 10.1111/j.1440-1797.2009.01261.x
- 601 61. Khattri RB, Kim K, Thome T, Salyers ZR, O'Malley KA, Berceli SA, Scali ST, Ryan TE. Unique  
602 Metabolomic Profile of Skeletal Muscle in Chronic Limb Threatening Ischemia. *Journal of  
603 Clinical Medicine*. 2021;10. doi: ARTN 548  
604 10.3390/jcm10030548
- 605 62. Yang L, He Y, Li X. Physical function and all-cause mortality in patients with chronic kidney  
606 disease and end-stage renal disease: a systematic review and meta-analysis. *Int Urol Nephrol*.  
607 2023;55:1219-1228. doi: 10.1007/s11255-022-03397-w
- 608 63. Ismaeel A, Franco ME, Lavado R, Papoutsi E, Casale GP, Fuglestad M, Mietus CJ, Haynatzki  
609 GR, Smith RS, Bohannon WT, et al. Altered Metabolomic Profile in Patients with Peripheral  
610 Artery Disease. *Journal of Clinical Medicine*. 2019;8. doi: ARTN 1463  
611 10.3390/jcm8091463
- 612 64. Ho KJ, Ramirez JL, Kulkarni R, Harris KG, Helenowski I, Xiong L, Ozaki CK, Grenon SM.  
613 Plasma Gut Microbe-Derived Metabolites Associated with Peripheral Artery Disease and Major  
614 Adverse Cardiac Events. *Microorganisms*. 2022;10. doi: 10.3390/microorganisms10102065
- 615 65. Razquin C, Ruiz-Canela M, Toledo E, Clish CB, Guasch-Ferre M, Garcia-Gavilan JF,  
616 Wittenbecher C, Alonso-Gomez A, Fito M, Liang L, et al. Circulating Amino Acids and Risk of  
617 Peripheral Artery Disease in the PREDIMED Trial. *Int J Mol Sci*. 2022;24. doi:  
618 10.3390/ijms24010270
- 619 66. Westbrook R, Chung T, Lovett J, Ward C, Joca H, Yang HL, Khadeer M, Tian J, Xue QL, Le  
620 AN, et al. Kynurenines link chronic inflammation to functional decline and physical frailty. *Jci  
621 Insight*. 2020;5. doi: ARTN 136091  
622 10.1172/jci.insight.136091

- 623 67. Cervenka I, Agudelo LZ, Ruas JL. Kynurenines: Tryptophan's metabolites in exercise,  
624 inflammation, and mental health. *Science*. 2017;357. doi: 10.1126/science.aaf9794
- 625 68. Xue C, Li G, Zheng Q, Gu X, Shi Q, Su Y, Chu Q, Yuan X, Bao Z, Lu J, et al. Tryptophan  
626 metabolism in health and disease. *Cell Metab*. 2023;35:1304-1326. doi:  
627 10.1016/j.cmet.2023.06.004

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646  
647  
648  
649  
650  
651  
652  
653  
654

655 **TABLE 1: Participant Characteristics**

	Control (N=28)	PAD (N=46)	CKD (N=31)	PAD+CKD (N=18)	<i>P</i> value ( $\chi^2$ test or One-way ANOVA)
<b>Physical Characteristics</b>					
Mean age, y (SD)	64.4 (12.0)	64.5 (8.6)	62.1 (12.4)	65.5 (9.0)	0.6869
Female sex, n (%)	8 (28.6)	18 (39.1)	13 (41.9)	9 (50.0)	0.5111
Non-White, n (%)	4 (14.3)	10 (21.7)	12 (38.7)	6 (33.3)	0.1366
Non-Hispanic, n (%)	26 (92.9)	40 (87.0)	31 (100.0)	18 (100.0)	0.0835
BMI, kg/m <sup>2</sup> (SD)	29.1 (6.3)	27.6 (6.0)	30.0 (6.9)	28.3 (6.5)	0.4777
<b>Disease Characteristics</b>					
ABI (SD)	1.00 (0.08)	0.60 (0.26)	1.04 (0.16)	0.65 (0.24)	<0.0001
TBI (SD)	0.81 (0.17)	0.36 (0.21)	0.75 (0.15)	0.34 (0.23)	<0.0001
BUN, (mg/dL) (SD)	15.8 (5.8)	14.6 (5.2)	35.0 (18.0)	38.8 (25.6)	<0.0001
Creatinine, (mg/dL) (SD)	0.9 (0.2)	0.9 (0.2)	4.4 (2.5)	3.9 (3.7)	<0.0001

eGFR, (mL/min/1.73m <sup>2</sup> ) (SD)	73.9 (19.3)	70.2 (17.0)	26.0 (12.2)	30.1 (16.2)	<0.0001
Tobacco use					
Former smoker, n (%)	18 (66.7)	44 (95.7)	9 (30.0)	14 (77.8)	<0.0001
Current smoker, n (%)	7 (25.9)	13 (28.3)	1 (3.3)	6 (33.3)	0.0303
Medical History					
Diabetes type I or II, n (%)	9 (32.1)	20 (43.5)	16 (51.6)	14 (77.8)	0.0208
Hypertension, n (%)	18 (64.3)	38 (82.6)	30 (96.8)	17 (94.4)	0.0042
Hyperlipidemia, n (%)	17 (60.7)	35 (76.1)	18 (58.1)	15 (83.3)	0.1416
Coronary artery disease, n (%)	10 (35.7)	23 (50.0)	7 (22.6)	6 (33.3)	0.1028
Congestive heart failure, n (%)	6 (21.4)	9 (19.6)	9 (29.0)	7 (38.9)	0.3890
Medication used					
Aspirin, n (%)	15 (53.6)	35 (76.1)	13 (41.9)	12 (66.7)	0.0183
ACE inhibitor, n (%)	5 (17.9)	17 (37.0)	7 (22.6)	4 (22.2)	0.2581
Angiotensin receptor blocker, n (%)	4 (14.3)	8 (17.4)	8 (25.8)	7 (38.9)	0.1869
Statin, n (%)	21 (75.0)	37 (80.4)	22 (71.0)	17 (94.4)	0.2509
Cilostazol, n (%)	0 (0.0)	14 (30.4)	0 (0)	4 (22.2)	0.0006
Beta Blocker, n (%)	14 (50.0)	25 (54.3)	19 (61.3)	15 (83.3)	0.1201
Anticoagulant, n (%)	3 (10.7)	17 (37.0)	8 (25.8)	8 (44.4)	0.0430
Antiplatelet, n (%)	5 (17.9)	12 (26.1)	7 (22.6)	2 (11.1)	0.5764
Abbreviations: BMI = body mass index; ABI = ankle-brachial index; TBI = toe-brachial index; BUN = blood urea nitrogen; eGFR = estimated glomerular filtration rate; ACE = angiotensin converting enzyme					

656

657

658

659

660

661 **FIGURE LEGENDS**

662 **Figure 1. Calf muscle strength and muscle fiber area is lowest in patients with PAD and CKD.** (A) Calf  
663 muscle strength in absolute and normalized to body weight (n=102). (B) Representative  
664 immunofluorescence images of gastrocnemius muscle biopsies with fiber types and sizes labeled. (C)  
665 Violin plots showing the cross-sectional areas of Type I (n=8816 myofibers) and Type II (n=8395)  
666 myofibers in each patient group (n=63 patients). (D) Quantification of the percentage of Type I fibers  
667 (n=63 patients). (E) Pearson correlation between calf muscle strength and mean myofiber area (both  
668 Type I and II myofibers) (n=43 patients). Panel A was analyzed using a Kruskal-Wallis Test with Dunn's  
669 test for pairwise comparisons. Panel C and D were analyzed using a one-way ANOVA with Tukey's post  
670 hoc testing. Error bars represent the standard deviation.

671

672 **Figure 2. Skeletal muscle mitochondrial function is significantly impaired in patients with CKD and**  
673 **PAD+CKD.** (A) Graphical depiction of mitochondrial analyses using permeabilized myofibers. (B)  
674 Relationship between oxygen consumption ( $JO_2$ ) and energy demand ( $\Delta G_{ATP}$ ) when mitochondria were  
675 fueled with pyruvate, malate, and octanoylcarnitine. (C) Quantification of the conductance (the slope of  
676  $JO_2$  and  $\Delta G_{ATP}$  relationship) (n=86 patients). (D) Citrate synthase activity in gastrocnemius muscle (n= 81  
677 patients). (E) Relationship between mitochondrial hydrogen peroxide production ( $JH_2O_2$ ) and energy  
678 demand ( $\Delta G_{ATP}$ ) when mitochondria were fueled with pyruvate, malate, and octanoylcarnitin. (F)  
679 Quantification of  $JH_2O_2$  under state 2 (no energy demand) conditions (n=82 patients). (G) Quantification  
680 of  $JH_2O_2$  with mitochondrial fueled with succinate followed by inhibition of the matrix antioxidant  
681 systems (with AF/BCNU) (n=85 patients). Analyzed via two-way ANOVA with Tukey's post hoc. (H)  
682 Representative images and quantification of succinate dehydrogenase (SDH) activity in muscle sections  
683 (n= patients).

684 Panels C, D, F, and H were analyzed with a one-way ANOVA with Tukey's post hoc. Error bars represent  
685 the standard deviation.

686

687 **Figure 3. CKD profoundly impacts the plasma metabolome independent of PAD.** (A) Targeted plasma  
688 metabolomic quantification of uremic toxins (n=97 patients). Analysis done using one-way ANOVA with  
689 Tukey's post hoc. (B) Graphic of experimental design and overall metabolite detection for untargeted  
690 (global) metabolomics in patient plasma. (C) Principal component analysis demonstrates separation  
691 between CKD and non-CKD patients, independent of PAD. (D) A heatmap with hierarchical clustering of  
692 metabolites and patients. (E) Venn diagram showing significant metabolite differences across group  
693 comparisons. Error bars represent the standard deviation.

694

695 **Figure 4. Uremic toxin levels have an inverse relationship with calf muscle mitochondrial function and**  
696 **strength.** (A) Pearson correlations between OXPHOS conductance and L-Kynurenine, L-Kyn/Trp ratio,



697 and indoxyl sulfate levels (n=81 patients). **(B)** Pearson correlations between calf muscle strength and L-  
698 Kynurenine, L-Kyn/Trp ratio, and indoxyl sulfate levels (n=72 patients). Statistical analyses performed  
699 using two-tailed Pearson correlation.

700

701 **Figure 5. Whole muscle and single nucleus RNA sequencing identify mitochondrial deficiency and**  
702 **cytoplasmic translation defects in patients with PAD+CKD. (A)** RNA sequencing on total RNA from the  
703 gastrocnemius was performed (n=88 patients). Partial least squares discriminant analysis (PLS-DA)  
704 revealed clear separation between PAD and PAD+CKD patients. **(B)** Volcano plot of gene expression  
705 shows differentially expressed genes in PAD and PAD+CKD patients. **(C)** Gene set enrichment analysis in  
706 significantly upregulated and downregulated genes between PAD and PAD+CKD patients. **(D)** Single  
707 nucleus RNA sequencing was performed on gastrocnemius muscle specimens from 20 PAD and 12  
708 PAD+CKD patients. UMAPs presented by group and by cell types are shown. **(E)** Percentage of nuclei  
709 within each cluster determined by group. **(F)** Dotplots of the top 4 marker genes for each cell type. **(G)**  
710 UMAPs of the subclustering of myofiber nuclei by group and type. **(H)** Venn diagrams shown  
711 differentially expressed genes by myonuclei type. **(I)** UMAPs showing the mitochondrial gene module  
712 score for each nuclei demonstrated the mitochondrial deficiency in PAD+CKD muscles. **(J)** Gene set  
713 enrichment analysis results for myonuclei populations. The x-axis is the normalized enrichment score  
714 and the values for each bar are the adjusted *P*-values.

715

716 **Figure 6. Fibro-adipogenic progenitor cells are uniquely remodeled in muscles from patients with**  
717 **PAD+CKD. (A)** UMAPs of the subclustering of FAPs presented by group and by subpopulation type are  
718 shown. **(B)** Donut plots showing the abundance of subpopulations of FAPs in both groups. **(C)** Ranked  
719 significant ligand-receptor communications for relative information flow between AHR<sup>fl/fl</sup> and AHR<sup>mKO</sup>  
720 muscles. **(D)** Trajectory inference in FAPs showed three distinct fates in PAD+CKD. **(E)** Feature plots  
721 showing normalized gene expression levels for inflammatory, pro-fibrotic, and adipogenic genes. **(F)**  
722 Gene expression changes across those three fates across pseudotime for both groups.

723

724 **Figure 7. CellChat analysis predicts changes in intercellular communication of PAD+CKD patients. (A)**  
725 Circle plots showing the overall intercellular communication occurring in non-PAD and PAD. Circle sizes  
726 represent the number of cells and edge width represents communication probability. **(B)** Comparison of  
727 outgoing and incoming interaction strengths for all cells type in non-PAD and PAD. **(C)** Ranked significant  
728 ligand-receptor communications for relative information flow between non-PAD and PAD muscles. **(D)**  
729 Circle plots for FGF signaling communication in non-PAD and PAD.

730

731

732

733

734

735

736

737

738

739

740

741 **NOVELTY AND SIGNIFICANCE**

742

743 **What is known?**

- 744
- 745 • Peripheral artery disease (PAD) patients with chronic kidney disease (CKD) have poorer health
  - 746 outcomes and increased risk for adverse limb events and mortality compared with patients with
  - 747 normal kidney function.
  - 748 • The accumulation of uremic toxins in CKD have been associated with adverse limb events in
  - 749 patients that have PAD.

749

750 **What new information does this article contribute?**

- 751
- 752 • Patients with PAD and CKD have significantly lower calf muscle strength, muscle fiber size, and
  - 753 mitochondrial function compared to PAD patients with normal kidney function.
  - 754 • CKD, but not PAD alone, has a significant impact on the plasma metabolome.
  - 755 • Uremic toxins such as indoxyl sulfate and L-Kynurenine have significant inverse relationships
  - 756 with calf muscle strength and mitochondrial function.
  - 757 • Bulk and single nucleus RNA sequencing reveals a mitochondrial deficiency in myofibers and
  - 758 pro-fibrotic/pro-adipogenic differentiation states of fibro-adipogenic progenitor cells in patients
  - 759 with PAD and CKD.

759

760 There is overwhelming evidence that PAD patients with CKD have significantly higher risk of major

761 adverse limb events and death compared to PAD patients without CKD. Moreover, having CKD increases

762 the likelihood that endovascular and open revascularization procedures fail in patients with PAD.

763 Skeletal muscle pathologies have been shown to play important roles in both PAD and CKD

764 independently. Because skeletal muscle function is a strong predictor of morbidity and mortality, it is  
765 important to understand how CKD exacerbates the myopathy of PAD to improve medical management  
766 in these patients. In a cohort of 123 patients, calf muscle strength was lowest in PAD patients with CKD,  
767 although both those PAD and CKD alone were also significantly weaker than non-PAD and non-CKD  
768 controls. Muscle fiber atrophy was also evident and muscle fiber size correlated with calf muscle  
769 strength. Using calf muscle biopsies, we found that mitochondrial function was significantly impaired in  
770 patients with CKD and those with PAD+CKD. Significant inverse correlations were found between uremic  
771 toxins and muscle strength and mitochondrial function. Bulk and single nucleus RNA sequencing  
772 revealed the wide-ranging impact of CKD on the muscle transcriptome in patients with PAD. In  
773 summary, this study establishes CKD as a major driver of skeletal muscle pathology in patients with PAD.

774

775

776

777


778

779

780

781

782



783

784

785


786 **Figure 1. Calf muscle strength and muscle fiber area is lowest in patients with PAD and CKD.** (A) Calf  
 787 muscle strength in absolute and normalized to body weight (n=102). (B) Representative  
 788 immunofluorescence images of gastrocnemius muscle biopsies with fiber types and sizes labeled. (C)  
 789 Violin plots showing the cross-sectional areas of Type I (n=8816 myofibers) and Type II (n=8395)  
 790 myofibers in each patient group (n=63 patients). (D) Quantification of the percentage of Type I fibers  
 791 (n=63 patients). (E) Pearson correlation between calf muscle strength and mean myofiber area (both  
 792 Type I and II myofibers) (n=43 patients). Panel A was analyzed using a Kruskal-Wallis Test with Dunn's  
 793 test for pairwise comparisons. Panel C and D were analyzed using a one-way ANOVA with Tukey's post  
 794 hoc testing. Error bars represent the standard deviation.

795

796

797

798




799

800 **Figure 2. Skeletal muscle mitochondrial function is significantly impaired in patients with CKD and**  
 801 **PAD+CKD.** (A) Graphical depiction of mitochondrial analyses using permeabilized myofibers. (B)  
 802 Relationship between oxygen consumption ( $JO_2$ ) and energy demand ( $\Delta G_{ATP}$ ) when mitochondria were  
 803 fueled with pyruvate, malate, and octanoylcarnitine. (C) Quantification of the conductance (the slope of  
 804  $JO_2$  and  $\Delta G_{ATP}$  relationship) ( $n=86$  patients). (D) Citrate synthase activity in gastrocnemius muscle ( $n=81$   
 805 patients). (E) Relationship between mitochondrial hydrogen peroxide production ( $JH_2O_2$ ) and energy  
 806 demand ( $\Delta G_{ATP}$ ) when mitochondria were fueled with pyruvate, malate, and octanoylcarnitine. (F)

807 Quantification of  $JH_2O_2$  under state 2 (no energy demand) conditions (n=82 patients). (G) Quantification  
 808 of  $JH_2O_2$  with mitochondrial fueled with succinate followed by inhibition of the matrix antioxidant  
 809 systems (with AF/BCNU) (n=85 patients). Analyzed via two-way ANOVA with Tukey's post hoc. (H)  
 810 Representative images and quantification of succinate dehydrogenase (SDH) activity in muscle sections  
 811 (n= patients).

812 Panels C, D, F, and H were analyzed with a one-way ANOVA with Tukey's post hoc. Error bars represent  
 813 the standard deviation.




814  
 815  
 816 **Figure 3. CKD profoundly impacts the plasma metabolome independent of PAD.** (A) Targeted plasma  
 817 metabolomic quantification of uremic toxins (n=97 patients). Analysis done using one-way ANOVA with  
 818 Tukey's post hoc. (B) Graphic of experimental design and overall metabolite detection for untargeted  
 819 (global) metabolomics in patient plasma. (C) Principal component analysis demonstrates separation  
 820 between CKD and non-CKD patients, independent of PAD. (D) A heatmap with hierarchical clustering of  
 821 metabolites and patients. (E) Venn diagram showing significant metabolite differences across group  
 822 comparisons. Error bars represent the standard deviation.

823

824

825

826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837



838  
839

840 **Figure 4. Uremic toxin levels have an inverse relationship with calf muscle mitochondrial function and**  
841 **strength. (A)** Pearson correlations between OXPHOS conductance and L-Kynurenine, L-Kyn/Trp ratio,  
842 and indoxyl sulfate levels (n=81 patients). **(B)** Pearson correlations between calf muscle strength and L-  
843 Kynurenine, L-Kyn/Trp ratio, and indoxyl sulfate levels (n=72 patients). Statistical analyses performed  
844 using two-tailed Pearson correlation.

845

846

847

848

849

850

851

852

853

854

855

856

857


858

859

860

861





862

863

864 **Figure 5. Whole muscle and single nucleus RNA sequencing identify mitochondrial deficiency and**  
 865 **cytoplasmic translation defects in patients with PAD+CKD. (A)** RNA sequencing on total RNA from the  
 866 gastrocnemius was performed (n=88 patients). Partial least squares discriminant analysis (PLS-DA)  
 867 revealed clear separation between PAD and PAD+CKD patients. **(B)** Volcano plot of gene expression  
 868 shows differentially expressed genes in PAD and PAD+CKD patients. **(C)** Gene set enrichment analysis in  
 869 significantly upregulated and downregulated genes between PAD and PAD+CKD patients. **(D)** Single  
 870 nucleus RNA sequencing was performed on gastrocnemius muscle specimens from 20 PAD and 12  
 871 PAD+CKD patients. UMAPs presented by group and by cell types are shown. **(E)** Percentage of nuclei  
 872 within each cluster determined by group. **(F)** Dotplots of the top 4 marker genes for each cell type. **(G)**  
 873 UMAPs of the subclustering of myofiber nuclei by group and type. **(H)** Venn diagrams shown  
 874 differentially expressed genes by myonuclei type. **(I)** UMAPs showing the mitochondrial gene module  
 875 score for each nuclei demonstrated the mitochondrial deficiency in PAD+CKD muscles. **(J)** Gene set  
 876 enrichment analysis results for myonuclei populations. The x-axis is the normalized enrichment score  
 877 and the values for each bar are the adjusted *P*-values.

878


879

880

881

882


883



884

885 **Figure 6. Fibro-adipogenic progenitor cells are uniquely remodeled in muscles from patients with**  
886 **PAD+CKD. (A) UMAPs of the subclustering of FAPs presented by group and by subpopulation type are**

887 shown. **(B)** Donut plots showing the abundance of subpopulations of FAPs in both groups. **(C)** Ranked  
 888 significant ligand-receptor communications for relative information flow between  $AHR^{fl/fl}$  and  $AHR^{mKO}$   
 889 muscles. **(D)** Trajectory inference in FAPs showed three distinct fates in PAD+CKD. **(E)** Feature plots  
 890 showing normalized gene expression levels for inflammatory, pro-fibrotic, and adipogenic genes. **(F)**  
 891 Gene expression changes across those three fates across pseudotime for both groups.



892  
 893  
 894 **Figure 7. CellChat analysis predicts changes in intercellular communication of PAD+CKD patients. (A)**  
 895 Circle plots showing the overall intercellular communication occurring in non-PAD and PAD. Circle sizes  
 896 represent the number of cells and edge width represents communication probability. **(B)** Comparison of  
 897 outgoing and incoming interaction strengths for all cells type in non-PAD and PAD. **(C)** Ranked significant  
 898 ligand-receptor communications for relative information flow between non-PAD and PAD muscles. **(D)**  
 899 Circle plots for FGF signaling communication in non-PAD and PAD.

900